Lifecore Biomedical Inc(LFCR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | - | Insider Own | 9.62% | Shs Outstand | 37.7M | Perf Week | -5.29% |
| Market Cap | 0.16B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 34.2M | Perf Month | -13.63% |
| Enterprise Value | 0.35B | PEG | - | EPS next Q | - | Inst Own | 67.27% | Short Float | 7.08% | Perf Quarter | -27.08% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | -0.29% | Short Ratio | 14.06 | Perf Half Y | -37.67% |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 2.42M | Perf YTD | -49.63% |
| Book/sh | -0.9 | P/C | 9.05 | EPS past 3/5Y | 31.55% 0.55% | ROE | - | 52W High | -54.12% ($8.98) | Perf Year | -46.98% |
| Cash/sh | 0.46 | P/FCF | - | Sales past 3/5Y | 5.02% -26.24% | ROIC | - | 52W Low | 13.66% ($3.62) | Perf 3Y | -44.85% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -430.88% | Gross Margin | - | Volatility(W/M) | 6.36% 5.46% | Perf 5Y | -61.13% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.25 | Perf 10Y | -66.99% |
| Dividend Ex-Date | - | Quick Ratio | 2.69 | EPS Q/Q | -243.04% | Profit Margin | - | RSI (14) | 38.09 | Recom | 1.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.87 | Sales Q/Q | -6.25% | SMA20 | -7.45% ($4.45) | Beta | 1.05 | Target Price | $6.75 |
| Payout | - | Debt/Eq | 9.72 | Earnings | 2026/8/5 | SMA50 | -9.79% ($4.57) | Rel Volume | 0.93 | Prev Close | $4.09 |
| Employees | - | LT Debt/Eq | 9.64 | EPS/Sales Surpr. | 7.44% 18.47% | SMA200 | -29.75% ($5.86) | Avg Volume(3M) | 0.17M | Price | $4.12 |
| IPO | 1996/2/15 | Option/Short | Yes/Yes | Trades | 1279 | Volume | 159,515 | Change | 0.73% |
Company
LFCR is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💉 LifeCore Biomedical (LFCR) is a U.S. healthcare company built around two core pillars: contract development and manufacturing of injectables, and the production of injectable hyaluronic acid. The company specializes in aseptic filling and finishing of sterile injectables in syringes, vials, and cartridges, along with complex formulation development. It is a specialized player in the branded and generic pharmaceutical space, leveraging long-cultivated expertise in manufacturing premium-grade injectable hyaluronic acid.
Over the past 1 year, on the lower side
54% below its 1-year high.
LFCR has weak earning power
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -44.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 67.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ORR 0.01%
OPPJ 0.00%
DFJ 0.00%
FDTS 0.00%
AVDV 0.00%It ranks #4 in the industry
Based on market cap of $156M.
LFCR $156M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is LFCR?
LFCR belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of LFCR?
The market cap of LFCR is approximately $156M, ranking 4,279 within its sector.
What is the 52-week high and low for LFCR?
LFCR has recorded a 52-week high of $8.98 and a low of $3.62.
